top of page

Allergan signs $1.5bn licensing deal for AstraZeneca’s inflammatory diseases drug

Allergan could pay as much as $1.52bn to MedImmune, the global biologics research and development arm of AstraZeneca, for the worldwide rights to an inflammatory diseases drug.

The drug, MEDI2070, is currently being tested in mid-stage clinical trials for patients with moderate-to-severe Crohn’s disease and ulcerative colitis.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page